Manuela Colafigli

Summary

Country: Italy

Publications

  1. pmc The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study
    Andrea De Luca
    University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy
    BMC Infect Dis 13:414. 2013
  2. doi request reprint Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
  3. doi request reprint Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
  4. doi request reprint Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
  5. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
  6. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
  7. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
  8. doi request reprint Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST
    Massimiliano Fabbiani
    From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome
    Scand J Infect Dis 46:34-45. 2014
  9. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
  10. ncbi request reprint Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE)
    Benedetta Milanini
    a Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Clin Neuropsychol 30:1457-1468. 2016

Collaborators

Detail Information

Publications29

  1. pmc The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study
    Andrea De Luca
    University Division of Infectious Diseases, University Hospital of Siena, Siena, Italy
    BMC Infect Dis 13:414. 2013
    ..Aim of the study was to evaluate whether hsCRP or other biomarkers are independent predictors of CVD risk in HIV-infected patients...
  2. doi request reprint Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of S Heart, Rome, Italy
    Clin Microbiol Infect 18:E299-304. 2012
    ..TDR significantly declined overall and for the single drug classes. Older age independently predicted increased odds of TDR, whereas a more recent GRT, a higher HIV-RNA and C vs. B subtype predicted lower odds of TDR...
  3. doi request reprint Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
    M Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    HIV Med 9:172-9. 2008
    ....
  4. doi request reprint Long-term follow-up of nevirapine-treated patients in a single-centre cohort
    Manuela Colafigli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    HIV Med 10:461-9. 2009
    ..We reviewed the safety and efficacy of nevirapine (NVP)-based therapy in all patients initiating NVP-containing combined antiretroviral therapy [cART (>or=3 drugs)] in our clinic since 1994...
  5. doi request reprint Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Antimicrob Chemother 68:1364-72. 2013
    ..To explore 48 week safety and efficacy of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression on a stable atazanavir/ritonavir-based standard triple regimen...
  6. doi request reprint Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1
    Laura Bracciale
    Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 25:261-7. 2009
    ..The achievement of virological suppression is a strong predictor of reduced clinical progression...
  7. ncbi request reprint Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
    Antivir Ther 12:835-9. 2007
    ..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort...
  8. doi request reprint Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RAST
    Massimiliano Fabbiani
    From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome
    Scand J Infect Dis 46:34-45. 2014
    ....
  9. ncbi request reprint Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    ..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed...
  10. ncbi request reprint Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE)
    Benedetta Milanini
    a Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Clin Neuropsychol 30:1457-1468. 2016
    ..Brief and sensitive screening tools are needed. We evaluated the accuracy of the Montreal Cognitive Assessment (MoCA) compared to the Mini Mental State Examination (MMSE) to detect cognitive impairment in HIV-infected participants...
  11. ncbi request reprint Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors
    Simona Di Giambenedetto
    Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
    Scand J Infect Dis 39:813-8. 2007
    ..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir...
  12. doi request reprint Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients
    Roberta Gagliardini
    a Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    J Chemother . 2016
    ....
  13. doi request reprint Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection
    Massimiliano Fabbiani
    a From the Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Infect Dis (Lond) 48:48-55. 2016
    ..The aim of the study was to explore relationships between self-reported adherence, antiretroviral drug concentration measurement (TDM) and self-reported symptoms...
  14. pmc Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients
    Massimiliano Fabbiani
    Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Infect Dis 14:26. 2014
    ..Aim of the study was to define if single tablet regimen (STR) as compared to bis-in-die (BID) or once-daily (OD) with ≥2 pills-a-day EFV formulations reduced the risk of interruption...
  15. pmc Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study
    Alessandra Latini
    San Gallicano Dermatologic Institute IRCCS, Clinic of Dermatology and Infectious Diseases, Rome, Italy
    BMC Infect Dis 16:401. 2016
    ..Aim of the study was to assess predictors of discontinuation/toxicity of boosted PI-based (PI/r) dual therapy (DT)...
  16. doi request reprint Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)
    Simona Di Giambenedetto
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Antimicrob Chemother . 2017
    ..The ATLAS-M trial explored 48 week non-inferior efficacy of simplification to atazanavir/ritonavir  +  lamivudine versus maintaining three-drug atazanavir/ritonavir-based cART in virologically suppressed patients...
  17. pmc Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping
    Mattia C F Prosperi
    Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
    Retrovirology 7:56. 2010
    ..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)...
  18. doi request reprint Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients
    Nicoletta Ciccarelli
    Department of Public Health, Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    Antivir Ther 20:433-40. 2015
    ..The aim of our study was to better understand the dynamics between cardiovascular risk factors and immunological parameters in the evolution of cognitive performance in HIV+ patients...
  19. pmc Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
    Mattia C F Prosperi
    Viral Immunodeficiency Unit, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    BMC Infect Dis 12:296. 2012
    ..However, its determinants are not fully understood. Aim of this study was to investigate predictors of first-line antiretroviral therapy discontinuation due to adverse events and their evolution in recent years...
  20. doi request reprint Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia
    Nicoletta Ciccarelli
    Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
    Antivir Ther 18:153-60. 2013
    ..The objective of our study was to compare two different central nervous system penetration-effectiveness (CPE) scores for the prediction of cognitive dysfunction in HIV-infected patients...
  21. doi request reprint The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy
    Angela Marzocchetti
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    AIDS Res Hum Retroviruses 27:1299-309. 2011
    ..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions...
  22. doi request reprint HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo Agostino Gemelli 8, 00168 Rome, Italy
    Vaccine 31:2914-8. 2013
    ..In conclusion, in HIV-infected patients influenza vaccination could have good efficacy in sustaining humoral response but cellular response appeared impaired...
  23. pmc Perceptions of Human Papillomavirus (HPV) infection and acceptability of HPV vaccine among men attending a sexual health clinic differ according to sexual orientation
    Massimo Giuliani
    a STI HIV Unit, UOC Dermatologia Infettiva e Allergologica, San Gallicano Dermatological Institute IRCCS, Rome, Italy
    Hum Vaccin Immunother 12:1542-50. 2016
    ..53-7.17; p=0.002). Efforts should be made to maximize awareness of HPV, especially as a causative agent of genital warts and male cancers, and to reinforce positive attitudes toward vaccination among men visiting STI centers. ..
  24. pmc Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
    Massimiliano Fabbiani
    Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Int AIDS Soc 17:19808. 2014
    ....
  25. pmc Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
    Mauro Zaccarelli
    Clinical Department, National Institute for the Infectious Diseases Lazzaro Spallanzani, Rome, Italy
    J Int AIDS Soc 17:19802. 2014
    ..To assess the role of drugs used in dual therapy (DT), as cART simplification, over the risk of treatment failure...
  26. ncbi request reprint Interpretation systems for genotypic drug resistance of HIV-1
    Andrea De Luca
    Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
    Scand J Infect Dis Suppl 106:29-34. 2003
    ..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation...
  27. pmc Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
    Roberta Gagliardini
    Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
    J Int AIDS Soc 17:19818. 2014
    ..There are few observations about MVC use in simplified treatment of coinfected patients...
  28. pmc Prevalence of anal human papillomavirus infection and cytologic abnormalities among HIV-infected and HIV-uninfected men who have sex with men
    Alessandra Latini
    Infectious Dermatology and Allergology Unit, San Gallicano Dermatologic Institute, IRCCS, Rome, Italy
    J Int AIDS Soc 17:19662. 2014
    ..Cytology may be a useful tool for the detection of anal precancerous lesions. We assessed the prevalence and determinants of anal HPV infection and cytologic abnormalities among HIV-infected and -uninfected MSM...
  29. ncbi request reprint HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence
    Tatiana Koudriavtseva
    Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Via Montpellier 1, 00133, Rome, Italy
    J Neurovirol . 2016
    ..CD4/CD8 ratio was lower in female HIV non-responders and in relapsing MS women compared, respectively, to female HIV responders and remitting MS women, and there were no differences in men...